It has long been appreciated that voltage-gated Na⁺ channels (VGSCs) underlie the upstroke of the action potential, and therefore play an essential role in the propagation of action potentials along axons (Hodgkin and Huxley, 1952a, 1952b). VGSCs consist of an alpha subunit, responsible for all essential features of a functional channel and up to two beta subunits that influence channel density and/or gating properties (Yu et al., 2005). Nine alpha subunits and four beta subunits have been identified. VGSCs have remained a target for the development of novel therapeutics because it is now also appreciated that changes in the biophysical properties (Cantrell and Catterall, 2001), distribution (Cusdin et al., 2008; Kuba et al., 2010), and/or expression (Aptowicz et al., 2004; Qiao et al., 2013) of these channels contributes to the dynamic regulation of neuronal excitability. Such changes have been particularly well documented in the context of pain, where both phosphorylation-dependent increases in Na⁺ current, as well as more persistent increases in VGSC expression, have been shown to underlie both the acute and persistent increases in nociceptor excitability associated with inflammation (Gold et al., 1996; Gould et al., 1998). Similarly, both the ongoing pain and hypersensitivity associated with peripheral nerve injury are associated with changes in the pattern of VGSC expression (Gold et al., 2003; Waxman et al., 1994; Hunter et al., 1997) as well as distribution of channels in peripheral nerves (Gold et al., 2003; Henry et al., 2007; Tseng et al., 2014). From a therapeutic perspective, what has been particularly exciting about the evidence implicating VGSCs in inflammatory and neuropathic pain, is that several of the VGSC alpha subunits shown to contribute to the injury-induced increases in afferent excitability are preferentially expressed in the peripheral nervous system in general, and nociceptive afferents in particular (Gold and Gebhart, 2010). This has raised the intriguing possibility that a VGSC subtype specific blocker would provide effective pain relief with minimal side effects.

Evidence in support of a role of VGSCs in a variety of pain states obtained with pre-clinical, largely rodent models, has been confirmed in pain patients. Similarly, genetic and anatomical evidence suggests that the VGSC alpha and beta subunits, and their pattern of expression, are similar in rodents and man. Nevertheless, virtually all that is known about the biophysical and pharmacological properties of VGSCs comes from the study of these channels in heterologous expression systems and in isolated rodent sensory neurons. The potential problem with this situation is highlighted by evidence that both the biophysical and pharmacological properties of channels are influenced by the expression system and species differences. For example, co-expression of VGSC beta1 and beta2-subunits with the alpha subunit NaV1.2 in frog oocytes not only increases current density, but the rate of current inactivation (Patton et al., 1994). In contrast, these beta-subunits have no influence on either current density or inactivation when co-expressed with NaV1.2 in tsA-201 cells (Qu et al., 2001). Rather, in tsA-201 cells, the beta-subunits drive a rightward shift in the voltage-dependence of channel activation. Similarly, the putatively NaV1.8 selective blocker A-803467 is over three orders of magnitude more potent against heterologously expressed human NaV1.8 than four of the other nine human alpha subunits tested, yet is only half as potent against the current believed to reflect activation of NaV1.8 channels, natively expressed in rat dorsal root ganglion neurons (Jarvis et al., 2007). Thus, the purpose of the present study was to determine the extent to which the biophysical and pharmacological properties of VGSCs described in rodent sensory neurons reflect the properties of the VGSCs in human sensory neurons. We focused on the two major classes of current that have been most extensively studied in rodent sensory neurons, those historically referred to as the low threshold rapidly activating, rapidly inactivating tetrodotoxin (TTX) sensitive current, and the high threshold more slowly activating and slowly inactivating TTX-resistant current, although voltage-protocols were used to isolate the putative TTX-resistant current in the majority of experiments described.

Whole cell patch clamp techniques were used to study acutely dissociated dorsal root ganglion (DRG) neurons from rats and humans. Our results suggest that while the two major Na⁺ current types in neurons from rats are similar to those in neurons from humans, there are several potentially important pharmacological and biophysical differences that could contribute to the limited success in the development of novel pain therapeutics.

Neurons included in this study were obtained from 21 donors (13 males and 8 females). The average age of the donors was 45.2 years with a range of 13 to 77. Additional demographic data are summarized in Table 1. At least one data point was obtained from a total of 226 neurons that met inclusion criteria for clamp control and holding current. In order to maximize the amount of data collected from each neuron, we first determined whether it was possible to use voltage-clamp protocols to isolate the rapidly activating rapidly inactivating putative TTX sensitive (TTX-S) Na⁺ current from the more slowly activating and slowly inactivating TTX-resistant (TTX-R) Na⁺ current, as we have previously done in the rat (Gold et al., 2003). We subsequently confirmed that currents isolated in this manner were identical to those isolated with TTX (Figure 1). Based on these results, we refer to the slowly activating and slowly inactivation current resistant to steady-state inactivation as TTX-R current even though voltage steps rather than TTX was used to isolate this current in all subsequent experiments.

Figure 1

Download asset Open asset

Figure 1—source data 1

Data plotted in Figure 1.

Data for Figure B top row on the right in the first columns. TTX-S current isolated by TTX and voltage are in columns J and K. Inactivation data plotted in Figure 1A right are in columns N-Q. Raw data in Figure 1A are in columns S-F, with the expanded time scale of these data in Figure 1B in columns AH-AU. IV data in Figure 1C are in the remaining columns.

https://doi.org/10.7554/eLife.23235.004

Download elife-23235-fig1-data1-v1.xlsx

We initially focused on the small to medium diameter DRG neurons from both human and rat in this study for two main reasons. First, because the study of Na⁺ channels in sensory neurons has largely been in the context of pain. In this context, data from guinea pig and rodents suggest that neurons with a small to medium cell body diameter are more likely to give rise to slowly conducting axons (Lawson, 2002), which are, in turn, more likely to be nociceptive. Second, it was more difficult to maintain clamp control over the currents evoked from human sensory neurons with a larger cell body diameter. Our decision about the size range in which to consider a human DRG neuron small- or medium-diameter was based on the distribution of cell body sizes observed in crysections of whole ganglia obtained from three donors (Figure 2A, inset). Interestingly, in contrast to the skewed, clearly bimodal distribution of DRG neuron cell body sizes previously described in rodents (i.e., see [Lawson et al., 1993]), human DRG neuron cell body sizes were relatively normally distributed. We therefore included a subpopulation of larger neurons in subsequent experiments to further test the association between cell body diameter and phenotype in human DRG neurons. The average membrane capacitance of all the neurons included in this study was 116 pF (or ~60 ± 0.8 μm in diameter), with a range from 23 to 255 pF (or 26 to 90 μm). A histogram of the size distribution is plotted in Figure 2. As expected, human DRG neurons are significantly larger than small to medium (cell body diameter < 35 μm) rat DRG neurons, which had an average cell body capacitance of 36 pF, with a range of 22 to 70 pF (Figure 2A). Consistent with previous evidence from the rat suggesting that TTX-R currents are enriched in nociceptive afferents (Djouhri et al., 2003), which tend to have a small cell body diameter (Lawson, 2002), no TTX-R current was detected in rat neurons with a cell body capacitance >55 pF. Conversely, there was no correlation (p>0.05) between human DRG neuron cell body diameter and TTX-R current density, or the ratio of TTX-S to TTX-R current, and TTX-R currents were present in the largest neuron studied. Furthermore, the average capacitance of the nine neurons studied in which only TTX-S current was detected, 83.2 ± 18 pF, was, if anything, smaller (p=0.059), than that of the population of neurons with both TTX-S and TTX-R currents.

Figure 2

Download asset Open asset

Figure 2—source data 1

Data plotted in Figure 2.

The data for the Inset to Figure 2A are in columns B-H, with both the total number of neurons counted from frozen sections and the total studied with patch clamp electrophysiology. The data for Figure 2A are in columns K-O. The data for Figure 2B are in columns Q-S.

https://doi.org/10.7554/eLife.23235.006

Download elife-23235-fig2-data1-v1.xlsx

Despite normalizing for the differences in cell body capacitance, the density of both TTX-R and TTX-S current were significantly larger in neurons from human (−53.2 ± 6.8 pA/pF (n = 114) and −62.2 ± 4.3 pA/pF (n = 78), respectively) compared to those in rat neurons (−47.7 ± 3.3 pA/pF (n = 26) and −42.6 ± 4.6 pA/pF (n = 26), respectively). Furthermore, the ratio of TTX-S to TTX-R current density was significantly greater in human than rat DRG neurons (Figure 2B).

Inflammatory mediator-induced increase in both TTX-R and TTX-S currents in human DRG neurons

As the acute inflammatory mediator-induced potentiation of TTX-R currents in rat DRG neurons was one of the first observations driving a focus on these currents in the context of pain (Gold et al., 1996), we sought to determine the impact of inflammatory mediators on Na⁺ currents in human DRG neurons. An inflammatory soup, consisting of bradykinin (10 μM), histamine (1 μM) and prostaglandin E2 (1 μM), was applied to neurons following establishment of stable recordings. Consistent with previous results from rat and subsequently mouse sensory neurons (Yang and Gereau, 2004), TTX-R currents were increased within seconds following bath application of inflammatory soup (Figure 3). This increase saturated within ~90 s. Comparable results were obtained in 13 of 17 human neurons tested, resulting in an average increase in peak current of 15 ± 1%. Concomitantly, rates of current activation and inactivation were increased, 9 ± 0.8% and 12 ± 3%, respectively. Both the increase in peak current and the increase in current activation rate would contribute to an increase in excitability.

Figure 3

Download asset Open asset

Figure 3—source data 1

Data plotted in Figure 3.

Data for the TTX-R current in the top inset are in columns B-D. Data for the TTX-S current in the bottom inset in are in columns F-H. Pooled response of TTX-R current to inflammatory mediator are in columns J-L.

https://doi.org/10.7554/eLife.23235.008

Download elife-23235-fig3-data1-v1.xlsx

Changes in TTX-S currents were assessed in 10 of the 17 neurons in which inflammatory soup-induced changes in TTX-R currents were assessed. TTX-S currents were increased in four of these neurons by 30 ± 6% (Figure 3). However, in contrast to TTX-R currents, the increase in TTX-S current was not associated with changes in rates of current activation or inactivation.

Biophysical properties of TTX-R currents in rat and human DRG neurons

Because, as noted above, the vast majority of what is known about the biophysical and pharmacological properties of TTX-S and TTX-R currents in sensory neurons was derived from the study of rodent sensory neurons, we next sought to compare the biophysical and pharmacological properties of currents in human DRG neurons with those of currents in rat DRG neurons. Data were collected from DRG neurons obtained from eight rats under conditions identical to those used for the study of human DRG neurons with the same series of protocols. Data collection from these eight rats was interleaved with the collection of the last ~third of the human DRG neuron data, enabling the use of the same stock solutions of test reagents. The steady-state properties of TTX-R currents in rat DRG neurons were qualitatively similar to those in human DRG neurons. However, in contrast to previous results indicating that persistent TTX-R currents were larger in human DRG neurons (Han et al., 2015), we observed the opposite (Figure 4A and B), where the persistent current in rat neurons at −10 and 0 mV was significantly larger than that in human neurons (Figure 4C, p<0.01 two-way ANOVA with Holm-Sidak post hoc test). There were also small but significant differences in the V_0.5 of both inactivation (Figure 4D), and activation (Figure 4E), which were more hyperpolarized in human neurons (p<0.01). In contrast, recovery from inactivation (Figure 4F) was comparably rapid in neurons from both human and rat.

Figure 4

Download asset Open asset

Figure 4—source data 1

Data plotted in Figure 4.

Data for human raw currents in Figure 4A are in columns B-G. Data for rat raw currents in Figure 4B are in columns I-O. Data for Figure 4C are in columns Q-U. Data for Figure 4F are in columns X-AD. Data for Figure 4D are in columns AG-AL. Data for Figure 4E are in columns AN-AS.

https://doi.org/10.7554/eLife.23235.010

Download elife-23235-fig4-data1-v1.xlsx

The kinetic properties of TTX-R currents in neurons from rat and human were also qualitatively similar (Figure 5A and B) with comparable rates of current activation (Figure 5C) and inactivation (Figure 5D).

Figure 5

Download asset Open asset

Figure 5—source data 1

Data plotted in Figure 5.

Data for human raw currents in Figure 5A are in columns B-V. Data for Figure 5B are in columns X-AR. Data for Figure 5C are in columns AU-AY. Data for Figure 5D are in columns BA-BE.

https://doi.org/10.7554/eLife.23235.012

Download elife-23235-fig5-data1-v1.xlsx

Pharmacological properties of TTX-R currents in rat and human DRG neurons

Two experiments were performed to enable comparison of the pharmacological properties of TTX-R currents in rat and human DRG neurons. In the first, the impact of the putatively NaV1.8 selective channel blocker, A-803467, was assessed. While this compound was shown to be both highly selective and potent against human NaV1.8 in heterologous expression systems (Jarvis et al., 2007), we were unable to obtain any evidence of an A-803467-induced decrease in TTX-R current in human DRG neurons at concentrations between 3 and 100 nM (n = 3–7 per concentration, data not shown). It was only at the very highest concentration tested (1 μM), that small but consistent block of TTX-R current was observed (Figure 6A). The same concentration of A-803467 blocked over 50% of TTX-R current in rat DRG neurons (Figure 6B). The difference in fractional block between human and rat obtained with this concentration was statistically significant (Figure 6C, p<0.01).

Figure 6

Download asset Open asset

Figure 6—source data 1

Data plotted in Figure 6.

Data for human raw currents in Figure 6A are in columns F-H. Data for Figure 6B are in columns K-M. Data for Figure 6C are in columns B-D.

https://doi.org/10.7554/eLife.23235.014

Download elife-23235-fig6-data1-v1.xlsx

In the second pharmacological experiment, we assessed both resting and use-dependent block of TTX-R currents with lidocaine. The potency of lidocaine was comparable against resting TTX-R currents from rat and human DRG neurons (Figure 7A,B and C). However, not only did TTX-R currents from human DRG neurons demonstrate little use-dependent inactivation in the absence of lidocaine, there was no detectable use-dependent block of these currents in the presence of lidocaine (Figure 7A and D). This was in contrast to the use-dependent inactivation and block of TTX-R currents in rat DRG neurons in the absence and presence of lidocaine, respectively (Figure 7B and D, p<0.01 two-way ANOVA).

Figure 7

Download asset Open asset

Figure 7—source data 1

Data plotted in Figure 7.

Data for human raw currents in Figure 7A are in columns U-AG. Data for Figure 7B are in columns AI-AU. Data for Figure 7C are in columns B-G. Data for Figure 7D are in columns I-R.

https://doi.org/10.7554/eLife.23235.016

Download elife-23235-fig7-data1-v1.xlsx

Biophysical properties of TTX-S currents in rat and human DRG neurons

As with TTX-R currents, TTX-S currents in rat and human DRG neurons were qualitatively similar. There was also no significant difference between species with respect to the steady-state inactivation of TTX-S currents (Figure 8A). However, the voltage-dependence of TTX-S activation was significantly more hyperpolarized in human than in rat DRG neurons (Figure 8B, p<0.01). Furthermore, while over 80% of TTX-S current from human DRG neurons recovered from inactivation with a fast time-constant, only 50% of TTX-S current from rat DRG neurons recovered as rapidly (Figure 8C, p<0.01).

Figure 8

Download asset Open asset

Figure 8—source data 1

Data plotted in Figure 8.

Data for the plot in Figure 8A are in columns J-O. Data for the plot in Figure 8B are in columns B-G. Data for plot in Figure 8C are in columns R-X.

https://doi.org/10.7554/eLife.23235.018

Download elife-23235-fig8-data1-v1.xlsx

TTX-S current kinetics in neurons from rat and human were also qualitatively similar (Figure 9A - D). However, current activation rate in human DRG neurons was faster than that in rat DRG neurons across the voltage range of current activation that was tested (Figure 9C).

Figure 9

Download asset Open asset

Figure 9—source data 1

Data plotted in Figure 9.

Data for human raw currents in Figure 9A are in columns B-V. Data for Figure 9B are in columns X-AR. Data for Figure 9C are in columns AU-AZ. Data for Figure 9D are in columns BC-BH.

https://doi.org/10.7554/eLife.23235.020

Download elife-23235-fig9-data1-v1.xlsx

Pharmacological properties of TTX-S currents in rat and human DRG neurons

Four pharmacological experiments were also performed on TTX-S currents. The first was prompted by the initial observation that TTX-S currents in human DRG neurons were less sensitive to TTX than was our previous experience from rat DRG neurons. Consistent with this impression, there was a significant difference between TTX-S currents from rat and human DRG neurons with respect to the fraction of current blocked by 30 nM TTX. That is, only ~30% of the TTX-S current in human DRG neurons was blocked by this concentration of TTX (Figure 10A) in contrast to the >90% of current blocked in rat DRG neurons (Figure 10B). This difference was statistically significant (Figure 10C, p<0.01).

Figure 10

Download asset Open asset

Figure 10—source data 1

Data plotted in Figure 10.

Data for human raw currents in Figure 10A are in columns G-I. Data for Figure 10B are in columns B-D. Data for Figure 10C are in columns L-M.

https://doi.org/10.7554/eLife.23235.022

Download elife-23235-fig10-data1-v1.xlsx

Lidocaine was again used in the second experiment. In contrast to the results obtained with TTX-R currents, there were differences between rat and human DRG neurons with respect to the resting block of TTX-S current, where lidocaine was less potent in the rat than the human (Figure 11A,B and C, p<0.01). Furthermore, while TTX-S currents in neurons from both rat and human were subject to use-dependent inhibition in the absence of lidocaine (Figure 11A,B and D), the inhibition was significantly (p<0.01) greater in rat neurons, at least at 1 and 2 Hz (Figure 11D). In both human and rat neurons, lidocaine caused significant (p<0.01) use-dependent block (Figure 11A,B and D).

Figure 11

Download asset Open asset

Figure 11—source data 1

Data plotted in Figure 11.

Data for Figure 11B are in columns U-AG. Data for Figure 11C are in columns B-F. Data for Figure 11D are in columns I-R.

https://doi.org/10.7554/eLife.23235.024

Download elife-23235-fig11-data1-v1.xlsx

The third and fourth experiments we designed to begin to assess the channel subtypes underlying the TTX-S current, given a growing body of evidence pointing to NaV1.7 as a therapeutic target for the treatment of pain (Vetter et al., 2017). As an initial foray into this question, we assessed the presence of a low threshold ‘ramp current’ in human DRG neurons based on rodent and heterologous expression data suggesting that because of the relatively slow development of closed-state inactivation of NaV1.7 channels, this subunit was responsible for large, low threshold currents evoked with a ramp depolarization. Despite the presence of TTX-S currents in every neuron included in this analysis, we detected no evidence of a low threshold ramp current in human DRG neurons in response to a depolarizing ramp from −100 mV to 0 mV over 500 ms, following a 500 ms pre-pulse to −90 mV (Figure 12A). Rather, peak inward current evoked in response to the ramp was at −5.9 ± 0.6 mV (n = 74). Because closed state-inactivation of NaV1.7 in human neurons may develop more rapidly than in rodent sensory neurons, we next assessed the impact of the NaV1.7 selective blocker Pro-Tx II (Schmalhofer et al., 2008) on TTX-S current in human DRG neurons. Little if any detectable suppression of TTX-S currents was observed in response to concentrations as high as 30 nM in the 27 neurons tested (Figure 12B). While we tested three different lots of the toxin on human neurons, we did not confirm the efficacy of any of these on rat DRG neurons. Thus, because of the notorious difficulty in working with large peptides, it is possible that negative results with this toxin were due to experimental errors. Nevertheless, we did test a fourth lot of the toxin, handled identically to the previous three, on rat DRG neurons, and observed a 50.5 ± 13.7% reduction in TTX-S current in the five neurons tested with 10 nM Pro-Tx II (Figure 12B).

Figure 12

Download asset Open asset

Figure 12—source data 1

Data plotted in Figure 12.

Data for human raw currents in Figure 12A are in columns B-C. Data for raw currents in Figure 12B are in columns F-M. Data for XS currents Figure 12C are in columns P-BF. Data for XR currents in Figure 12C are in columns BH-CX. Data for Figure 12D are in columns DC-DI.

https://doi.org/10.7554/eLife.23235.026

Download elife-23235-fig12-data1-v1.xlsx

While the ramp current and Pro-Tx II data argued against the presence of NaV1.7 in human DRG neurons, recent results with a putatively NaV1.7 selective small molecule blocker, PF-05089771 suggested that the majority of TTX-S current in human DRG neurons is carried by NaV1.7 (Alexandrou et al., 2016). Thus, in the fourth set of experiments, we assessed the impact of PF-05089771 on human DRG neurons. Consistent with previous results (Alexandrou et al., 2016), we observed complete inhibition of TTX-S currents in human DRG neurons following a 30 min pre-incubation with PF-05089771 with concentrations as low as 30 nM (Figure 12C and D). Concentration-response data indicated that the IC50 for TTX-S current block was ~6 nM, close to that previously reported (Alexandrou et al., 2016). However, in contrast to the previous study of PF-05089771 on human DRG neurons, which was performed in the presence of A-803467, we assessed the impact of this compound on TTX-R currents. In striking contrast to the heterologous expression data indicating NaV1.8 is resistant to PF-05089771 at concentrations as high as 10 μM, we observed a significant reduction in TTX-R currents in neurons treated with this compound. In fact, the calculated IC50 for inhibition of TTX-R currents in human DRG neurons was ~50 nM (Figure 12C and D).

The purpose of the present study was to compare the properties of voltage-gated Na⁺ currents in DRG neurons from rat and human. As with currents in the rat, the major types of current, those classically described as the rapidly activating and rapidly inactivating TTX-S current, and the more slowly activing and slowly inactivating TTX-R current, were well isolated with voltage clamp protocols. In fact, an issue potentially relevant to the interpretation of our pharmacological experiments, voltage protocols were used to isolate these currents in all but our initial characterization experiments. Both types of current were potentiated by inflammatory mediators, although TTX-S currents were increased in only a subpopulation of neurons in which TTX-R currents were increased. The biophysical properties of TTX-R currents in human DRG neurons were qualitatively similar to those in rat DRG neurons, with small, but significant differences in the V_0.5 of current inactivation and activation. However, in contrast to TTX-R current in rat DRG neurons, there was little evidence of use-dependent inactivation of currents in human DRG neurons. There were also significant differences in the extent of the block produced by the putatively NaV1.8 selective blocker A-803467, as well as the use-dependent block produced by lidocaine, both of which were significantly smaller on currents from human DRG neurons. As with TTX-R currents, TTX-S currents in rat and human DRG neurons were qualitatively similar. However, the V_0.5 of current activation was more hyperpolarized, a larger fraction of current recovered rapidly from inactivation, and the currents activated significantly faster in human DRG neurons. The potency of TTX was significantly lower against currents in human DRG neurons. The lidocaine-induced use-dependent block of TTX-S currents was also smaller in human DRG neurons. Finally, there was no evidence of low threshold ramp currents in human DRG neurons, the TTX-S currents were resistant to the NaV1.7-selective blocker Pro-Tx II, and while TTX-S currents were blocked by PF-05089771, this putatively selective small molecule inhibitor of NaV1.7 also blocked TTX-R currents in human DRG neurons. These results have important implications for drug development, as well as our understanding of pain mechanisms.

With respect to drug development, the results of the present study are consistent with those from previous studies indicating that both expression systems and species differences may have a significant influence on the pharmacological properties of the protein in question. This may be particularly true for VGSC because of extensive post-translational modifications (Laedermann et al., 2015). Potentially more problematic is that these modifications may not only be cell type specific, but specific to location(s) within a given cell (Harriott and Gold, 2008). In the context of pharmacology, where side effects are often due to off-target actions of a drug, any decrease in relative potency increases the likelihood of side effects. We observed a loss of selectivity in human DRG neurons for both A-803467 and PF-05089771. In the case of the former, we observed a decrease in TTX-S current in human DRG neurons in response to 1 μM A-803467 which was close to that of TTX-R currents (data not shown), while in the case of the latter, we observed a block of TTX-R currents with an IC50 less than an order of magnitude higher than that for block of TTX-S currents. These results suggest that despite the very high degree of selectivity observed with these compounds on heterologously expressed VGSC, the therapeutic window for A-803467 would likely have been quite limited in the clinical setting, while any therapeutic effect of PF-05089771 may also reflect block of NaV1.8 channels. Similarly, the demonstration in heterologous expression systems that the potency of VGSC blockers may be state-dependent served as the rationale for the development of state-dependent VGSC blockers for the treatment of pain (Dick et al., 2007). That is, this observation suggested it may be possible to use such drugs to preferentially block spontaneous or aberrant activity, and thereby reduce spontaneous pain while preserving normal sensation. However, our observation that TTX-R currents in human DRG neurons, currents thought to play a critical role in spike initiation in nociceptive afferents, are subject to little if any use-dependent block in either the absence or presence of a prototypical use-dependent VGSC blocker could explain the limited therapeutic efficacy of local anesthetics (at least when delivered at concentrations below that needed to block action potential propagation) in pain patients (Finnerup et al., 2015).

There are several implications of the results of the present study with respect to our understanding of pain mechanisms. First, consistent with results from another recent study of human DRG neurons, our data confirm the utility of this model for the analysis and/or confirmation of second messenger systems implicated in the sensitization of putative nociceptive afferents. That is, it was recently demonstrated that application of inflammatory mediators to isolated human sensory neurons resulted in an increase in excitability (Davidson et al., 2014). Furthermore, activation of group II metabotropic glutamate receptors, shown to block the inflammatory mediator-induced sensitization of mouse sensory neurons, was also shown to block the sensitization of human sensory neurons (Davidson et al., 2016). Results of the present study confirm previous results from the study of rodent sensory neurons, suggesting that increases in both TTX-R (Gold et al., 1996) and TTX-S (Cardenas et al., 1997) currents are likely to contribute to this increase in excitability. The observation that TTX-S currents were only increased in a subpopulation of neurons in which TTX-R currents were increased, is interesting for at least two reasons. One is that it suggests that there is relatively tight coupling between G-proteins and effector molecules, even within the isolated sensory neurons. This would underscore the importance of getting a therapeutic intervention to the right place. Another reason the observation about the modulation of TTX-S and R currents is interesting is that it suggests that it may be necessary to reduce both TTX-R and TTX-S currents to achieve maximal pain relief.

Another implication of our results concerns assumptions about the relationship between cell body diameter and afferent function. That is, there is compelling evidence to suggest that at least for cutaneous afferents, nociceptors are enriched in the subpopulation with a small cell body diameter while low-threshold afferents are enriched in a subpopulation of neurons with a large cell body diameter (Lawson, 2002; Djouhri et al., 2003). Consistent with association between cell body size and function, NaV1.8 is not only enriched in nociceptive afferents (Djouhri et al., 2003), but is preferentially expressed in sensory neurons with a small cell body diameter. In contrast, neither the size distribution nor the distribution of TTX-R currents among human DRG neurons suggests that there is a comparable relationship between cell body size and function in the human as has been documented in the rodent. Given that we did not assess the currents present in the very largest human DRG neurons, it is possible that we missed the subpopulation of putative non-nociceptive afferents comparable to that in the rodent, but this would still suggest TTX-R currents are far more widely distributed in human neurons than in the rodent. In this regard, it is also possible that TTX-R currents play a more important role in non-nociceptive human than rodent neurons. However, our inflammatory mediator data, as well as previous excitability data from human DRG neurons (Davidson et al., 2014) suggests the association between TTX-R currents and the nociceptive phenotype is preserved in human DRG neurons. Minimally, these data suggest that additional criteria will be needed to identify putative subtypes of human sensory neurons in future studies.

A third implication of our results concerns the present model of spike initiation and the emergence of sustained activity following injury in putative nociceptive neurons. That is, data from the study of rodent sensory neurons suggests that spike initiation involves the initial activation of NaV1.7 followed by the activation of NaV1.8 (Cummins et al., 1998). This suggested NaV1.7 as a viable target to attenuate nociceptor activity. However, our data from human DRG neurons suggest that while the threshold for activation of TTX-S currents is more negative than that of TTX-R currents, the failure of TTX to block ramp currents in the nine neurons tested (data not shown) suggests that ramp currents are dominated by TTX-R currents. This suggests that TTX-R currents are responsible for both spike initiation and the action potential over-shoot in human DRG neurons. Similarly, while use-dependent block of TTX-R currents in rodent sensory neurons has been argued to contribute to the slow adaptation observed in nociceptive afferent in response to prolonged stimulation (Choi et al., 2007), the absence of use-dependent block of TTX-R currents in human DRG neurons would enable these channels to underlie sustained neural activity such as that associated with ongoing pain. Furthermore, the relatively fast and complete recovery from inactivation observed for human TTX-S currents suggests that even in the absence of injury, these currents would be able to contribute to a relatively high level of sustained activity. This is in contrast to current models of injury-induced changes in VGSC expression, where the upregulation of NaV1.3, a channel with a relatively rapid rate of recovery from inactivation (Cummins and Waxman, 1997), is thought to contribute to the increase in sensory neuron excitability observed following peripheral nerve injury.

Our data on the channel subunits underlying the TTX-S current in human DRG neurons also has important implications given the recent focus on NaV1.7 as a potential therapeutic target for the treatment of pain based on the human channelopathy data (Dib-Hajj et al., 2013). One interpretation of our PF-05089771 data is that NaV1.7 underlies most, if not all of the TTX-S current in human DRG neurons. This interpretation would be consistent with that proposed by Alexandrou and colleagues based on the selectivity of this compound on human Na⁺ channel subtypes expressed in HEK293 cells, as well as the impact of this compound on TTX-S current in human DRG neurons (Alexandrou et al., 2016). If this interpretation was correct, however, it would suggest that the biophysical properties of NaV1.7 in human DRG neurons, at least with respect to the relatively slow entry into an inactivated state, are different from that of human NaV1.7 channels expressed in HEK293 cells, or NaV1.7 channels in rodent sensory neurons (Cummins et al., 1998). That is, because closed state inactivation develops so much more slowly in heterologously expressed NaV1.7 channels than other subtypes such as NaV1.4, NaV1.7 was proposed to account for the large low threshold TTX-S current evoked with ramp depolarization of small rodent DRG neurons (Cummins et al., 1998). However, only high threshold ramp currents were evoked in human DRG neurons that were resistant to TTX. Furthermore, the interpretation that NaV1.7 is the dominant channel subtype underlying TTX-S currents in human DRG neurons would also suggest that the potency of Pro-Tx II is different for the block of NaV1.7 in human DRG neurons than in HEK 293 cells (Schmalhofer et al., 2008) or rodent sensory neurons (Laedermann et al., 2014).

An alternative interpretation of our results is that NaV1.7 may not be the dominant subunit underlying TTX-S currents, let alone significantly contribute to these currents in human DRG neurons. That is, while it is possible that PF-05089771 retains its selectivity for NaV1.7 over other natively expressed TTX-S channels, our observation that this compound blocks TTX-R currents in human DRG neurons with an IC50 of ~50 nM, yet has no activity at NaV1.8 channels in HEK293 cells at concentrations as high as 10 μM (Alexandrou et al., 2016) raises the possibility that there is a more generalized loss of selectivity of this compound against Na⁺ channels present in their native environment. Importantly, while the channel block produced by PF-05089771 was shown to be highly state-dependent in heterologous expression experiments, blocking inactivated channels with a potency almost four orders of magnitude higher than that of channels in a resting or closed state (Alexandrou et al., 2016), this property is unlikely to account for the apparent block of TTX-R currents observed in human DRG neurons. That is, the pre-pulse potential used to evoke TTX-R currents would have left the majority of channels underlying the TTX-R current in a closed or resting state (i.e., fully available for activation), and therefore should have decreased, rather than increased the potency of this compound. A relative dearth of NaV1.7 in human DRG neurons would also account for the absence of a low threshold TTX-S ramp current, as well as the absence of channel block with ProTx-II. A limited expression of NaV1.7 in a subpopulation of human DRG neurons would also explain why the inflammatory mediator-induced increase in TTX-S current was only detected in a subpopulation of neurons. It is important to point out that even in rodent sensory neurons, other TTX-S channel subunits are expressed at levels comparable to that of NaV1.7, at least in subpopulations of neurons. For example, RNAseq analysis of mouse DRG neurons suggests that the number of copies of NaV1.6 (31.1) is comparable to that of NaV1.7 (54), at least in the subpopulation of neurons not in the TRPV1 lineage (Goswami et al., 2014). Comparable results were obtained with a quantitative PCR analysis of single DRG neurons, where in those larger than 30 μm in diameter, NaV1.6 expression was comparable to that of NaV1.7 (Ho and O'Leary, 2011). It is also worth noting that despite evidence that NaV1.7 is distributed throughout sensory neurons (Black et al., 2012), recent evidence suggests that the contribution of NaV1.7 to even rodent sensory neurons may have been overestimated. That is, while the activity of the putatively NaV1.7 selective spider venom peptide Pn3a on native TTX-R currents was not well described, results with this peptide suggests that NaV1.7 does not even account for 50% of the TTX-S current in the majority of rat DRG neurons (Deuis et al., 2017). It should also be noted that recent data from the NaV1.7 null mutant mice suggest that this subunit may, in fact play a more important role in mediating Na⁺ influx and associated changes in gene expression than it does in the electrical properties of these neurons (Minett et al., 2015). And while compensation may account for the relatively limited impact of the NaV1.7 knock-out on TTX-S currents in mouse small diameter DRG neurons, the ~25% decrease in TTX-S current density observed in these neurons is consistent with a relatively limited contribution of NaV1.7 to the TTX-S current (Nassar et al., 2004). More relevantly, the suggestion that NaV1.7 contributes little to the TTX-S current in human sensory neurons is consistent with the relatively limited impact of gain of function mutations on the excitability of human nociceptive afferents (Namer et al., 2015).

While several potentially important differences were observed in the Na⁺ currents in human and rat DRG neurons, it is important to consider the extent to which these differences were due to experimental variables rather than species differences. Neurons were collected from both male and female human donors with an average age of 45 years, at least an hour after cross clamp. In contrast, neurons were obtained from relatively young (~60 day old) male rats that were deeply anesthetized at the time of tissue collection. Unfortunately, we were unable to rule out the time between cross-clamp and tissue collection as a factor contributing to the differences observed, as preliminary results indicated that the viability of rat DRG neurons fell off precipitously 15 min after death, even in rats perfused with ice-cold saline. However, we suggest that neither of the other two main factors were likely to contribute to the differences observed, as there was no detectable influence of either age (at least comparing neurons from young (<30) and old (>65) donors) or donor sex on the biophysical properties of Na⁺ currents assessed (data not shown). It is also possible that the larger currents and larger cell body size of human DRG neurons resulted in a decrease in clamp control that contributed to the hyperpolarizing shift in both TTX-R and TTX-S current G-V curves as well as the faster rates of current activation observed in human neurons. Arguing against this possibility, however, is the fact that while the slopes of the G-V curves for both current types were steeper in human than in rat neurons (4.8 ± 0.1 mV and 5.4 ± 0.2 mV vs 5.0 ± 0.1 mV and 6.3 ± 0.1 mV, for TTX-R and TTX-S currents in human and rat neurons, respectively), these small differences could not account for the observed differences in the V_0.5 of activation, nor are they consistent with a loss of clamp control, which would be predicted to result in a much larger decrease in the slope of the G-V curve. In addition, differences in the V_0.5 of activation persisted when data from only the smallest human and largest rat neurons were compared. For example, the V_0.5 of current activation for TTX-R in the overlapping subpopulation of rat and human sensory neurons were −2.1 ± 0.4 mV and −10.8 ± 1.7 mV, respectively.

We also suggest that it is unlikely that the recording conditions used, which were necessary to both minimize voltage-gated Ca²⁺ currents while maximizing patch stability had a significant influence on the biophysical properties of the currents recorded. That is, the properties of the currents observed in rat neurons recorded under conditions identical to those used for the study of human neurons, were comparable to those we have previously observed (Gold et al., 2003; Flake et al., 2004; Vaughn and Gold, 2010). That said, we have always used a relatively low concentration of extracellular Na⁺ to help maintain clamp control, and minimized Ca2+ current contamination with a reduction of extracellular Ca2+ and/or the use of extracellular Ca2+ channel blockers such as Cd2+. In contrast, others, who have reported considerably more hyperpolarized potentials for the activation and inactivation of both TTX-S and TTX-R currents in rat DRG neurons have used higher concentrations of extracellular Na⁺ as well as intracellular solutions containing fluoride (Cummins and Waxman, 1997; Roy and Narahashi, 1992; Rush and Elliott, 1997). It remains to be determined whether recording conditions have comparable influences on the biophysical properties of Na⁺ currents in human DRG neurons. Finally, it is important to point out that while we attempted to control for the impact of state-dependent properties of the compounds tested, our pharmacological results should be interpreted with caution because of the potentially confounding interaction between these properties and the voltage protocols used to isolate TTX-S from TTX-R currents.

In summary, we have described important similarities and differences between human and rat dorsal root ganglion neurons with respect to the biophysical and pharmacological properties of the two major classes of voltage-gated Na⁺ current. We would argue that the similarities were sufficient to justify the continued use of rodent sensory neurons as a model system with which to explore the potential contribution of a variety of channels critical to both pain and analgesia. However, we would also argue that the differences were sufficient to contribute to what continues to be a tremendously high failure rate in the development of novel analgesics. Use of human DRG neurons for the screening of potentially novel therapeutics targeting the primary afferent and/or proteins in the primary afferent may help rectify this situation, by enabling the identification of compounds unlikely to achieve the intended effect prior to the initiation of expensive clinical trials.

1. 1. Alexandrou AJ
   2. Brown AR
   3. Chapman ML
   4. Estacion M
   5. Turner J
   6. Mis MA
   7. Wilbrey A
   8. Payne EC
   9. Gutteridge A
   10. Cox PJ
   11. Doyle R
   12. Printzenhoff D
   13. Lin Z
   14. Marron BE
   15. West C
   16. Swain NA
   17. Storer RI
   18. Stupple PA
   19. Castle NA
   20. Hounshell JA
   21. Rivara M
   22. Randall A
   23. Dib-Hajj SD
   24. Krafte D
   25. Waxman SG
   26. Patel MK
   27. Butt RP
   28. Stevens EB

   (2016) Subtype-Selective small molecule inhibitors reveal a fundamental role for Nav1.7 in nociceptor electrogenesis, axonal conduction and presynaptic release

   PLoS One 11:e0152405.

   https://doi.org/10.1371/journal.pone.0152405

   • PubMed
   • Google Scholar
2. 1. Aptowicz CO
   2. Kunkler PE
   3. Kraig RP

   (2004) Homeostatic plasticity in hippocampal slice cultures involves changes in voltage-gated Na+ channel expression

   Brain Research 998:155–163.

   https://doi.org/10.1016/j.brainres.2003.11.035

   • PubMed
   • Google Scholar
3. 1. Black JA
   2. Frézel N
   3. Dib-Hajj SD
   4. Waxman SG

   (2012) Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn

   Molecular Pain 8:82.

   https://doi.org/10.1186/1744-8069-8-82

   • PubMed
   • Google Scholar
4. 1. Cantrell AR
   2. Catterall WA

   (2001) Neuromodulation of Na+ channels: an unexpected form of cellular plasticity

   Nature Reviews Neuroscience 2:397–407.

   https://doi.org/10.1038/35077553

   • PubMed
   • Google Scholar
5. 1. Cardenas CG
   2. Del Mar LP
   3. Cooper BY
   4. Scroggs RS

   (1997)

   5HT4 receptors couple positively to tetrodotoxin-insensitive sodium channels in a subpopulation of capsaicin-sensitive rat sensory neurons

   Journal of Neuroscience 17:7181–7189.

   • PubMed
   • Google Scholar
6. 1. Choi JS
   2. Dib-Hajj SD
   3. Waxman SG

   (2007) Differential slow inactivation and use-dependent inhibition of Nav1.8 channels contribute to distinct firing properties in IB4+ and IB4- DRG neurons

   Journal of Neurophysiology 97:1258–1265.

   https://doi.org/10.1152/jn.01033.2006

   • PubMed
   • Google Scholar
7. 1. Cummins TR
   2. Howe JR
   3. Waxman SG

   (1998)

   Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel

   Journal of Neuroscience 18:9607–9619.

   • PubMed
   • Google Scholar
8. 1. Cummins TR
   2. Waxman SG

   (1997)

   Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury

   Journal of Neuroscience 17:3503–3514.

   • PubMed
   • Google Scholar
9. 1. Cusdin FS
   2. Clare JJ
   3. Jackson AP

   (2008) Trafficking and cellular distribution of voltage-gated sodium channels

   Traffic 9:17–26.

   https://doi.org/10.1111/j.1600-0854.2007.00673.x

   • PubMed
   • Google Scholar
10. 1. Davidson S
    2. Copits BA
    3. Zhang J
    4. Page G
    5. Ghetti A
    6. Gereau RW

    (2014) Human sensory neurons: membrane properties and sensitization by inflammatory mediators

    Pain 155:1861–1870.

    https://doi.org/10.1016/j.pain.2014.06.017

    • PubMed
    • Google Scholar
11. 1. Davidson S
    2. Golden JP
    3. Copits BA
    4. Ray PR
    5. Vogt SK
    6. Valtcheva MV
    7. Schmidt RE
    8. Ghetti A
    9. Price TJ
    10. Gereau RW

    (2016) Group II mGluRs suppress hyperexcitability in mouse and human nociceptors

    PAIN 157:2081–2088.

    https://doi.org/10.1097/j.pain.0000000000000621

    • PubMed
    • Google Scholar
12. 1. Deuis JR
    2. Dekan Z
    3. Wingerd JS
    4. Smith JJ
    5. Munasinghe NR
    6. Bhola RF
    7. Imlach WL
    8. Herzig V
    9. Armstrong DA
    10. Rosengren KJ
    11. Bosmans F
    12. Waxman SG
    13. Dib-Hajj SD
    14. Escoubas P
    15. Minett MS
    16. Christie MJ
    17. King GF
    18. Alewood PF
    19. Lewis RJ
    20. Wood JN
    21. Vetter I

    (2017) Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a

    Scientific Reports 7:40883.

    https://doi.org/10.1038/srep40883

    • PubMed
    • Google Scholar
13. 1. Dib-Hajj SD
    2. Yang Y
    3. Black JA
    4. Waxman SG

    (2013) The na(V)1.7 sodium channel: from molecule to man

    Nature Reviews Neuroscience 14:49–62.

    https://doi.org/10.1038/nrn3404

    • PubMed
    • Google Scholar
14. 1. Dick IE
    2. Brochu RM
    3. Purohit Y
    4. Kaczorowski GJ
    5. Martin WJ
    6. Priest BT

    (2007) Sodium channel blockade may contribute to the analgesic efficacy of antidepressants

    The Journal of Pain 8:315–324.

    https://doi.org/10.1016/j.jpain.2006.10.001

    • PubMed
    • Google Scholar
15. 1. Djouhri L
    2. Fang X
    3. Okuse K
    4. Wood JN
    5. Berry CM
    6. Lawson SN

    (2003) The TTX-resistant sodium channel Nav1.8 (SNS/PN3): expression and correlation with membrane properties in rat nociceptive primary afferent neurons

    The Journal of Physiology 550:739–752.

    https://doi.org/10.1113/jphysiol.2003.042127

    • PubMed
    • Google Scholar
16. 1. Finnerup NB
    2. Attal N
    3. Haroutounian S
    4. McNicol E
    5. Baron R
    6. Dworkin RH
    7. Gilron I
    8. Haanpää M
    9. Hansson P
    10. Jensen TS
    11. Kamerman PR
    12. Lund K
    13. Moore A
    14. Raja SN
    15. Rice AS
    16. Rowbotham M
    17. Sena E
    18. Siddall P
    19. Smith BH
    20. Wallace M

    (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis

    The Lancet Neurology 14:162–173.

    https://doi.org/10.1016/S1474-4422(14)70251-0

    • PubMed
    • Google Scholar
17. 1. Flake NM
    2. Lancaster E
    3. Weinreich D
    4. Gold MS

    (2004) Absence of an association between axotomy-induced changes in sodium currents and excitability in DRG neurons from the adult rat

    Pain 109:471–480.

    https://doi.org/10.1016/j.pain.2004.02.024

    • PubMed
    • Google Scholar
18. 1. Gold MS
    2. Gebhart GF

    (2010) Nociceptor sensitization in pain pathogenesis

    Nature Medicine 16:1248–1257.

    https://doi.org/10.1038/nm.2235

    • PubMed
    • Google Scholar
19. 1. Gold MS
    2. Reichling DB
    3. Shuster MJ
    4. Levine JD

    (1996) Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors

    PNAS 93:1108–1112.

    https://doi.org/10.1073/pnas.93.3.1108

    • PubMed
    • Google Scholar
20. 1. Gold MS
    2. Weinreich D
    3. Kim CS
    4. Wang R
    5. Treanor J
    6. Porreca F
    7. Lai J

    (2003)

    Redistribution of na(V)1.8 in uninjured axons enables neuropathic pain

    Journal of Neuroscience 23:158–166.

    • PubMed
    • Google Scholar
21. 1. Goswami SC
    2. Mishra SK
    3. Maric D
    4. Kaszas K
    5. Gonnella GL
    6. Clokie SJ
    7. Kominsky HD
    8. Gross JR
    9. Keller JM
    10. Mannes AJ
    11. Hoon MA
    12. Iadarola MJ

    (2014) Molecular signatures of mouse TRPV1-lineage neurons revealed by RNA-Seq transcriptome analysis

    The Journal of Pain 15:1338–1359.

    https://doi.org/10.1016/j.jpain.2014.09.010

    • PubMed
    • Google Scholar
22. 1. Gould HJ
    2. England JD
    3. Liu ZP
    4. Levinson SR

    (1998) Rapid sodium channel augmentation in response to inflammation induced by Complete Freund's adjuvant

    Brain Research 802:69–74.

    https://doi.org/10.1016/S0006-8993(98)00568-X

    • PubMed
    • Google Scholar
23. 1. Han C
    2. Estacion M
    3. Huang J
    4. Vasylyev D
    5. Zhao P
    6. Dib-Hajj SD
    7. Waxman SG

    (2015) Human na(v)1.8: enhanced persistent and ramp currents contribute to distinct firing properties of human DRG neurons

    Journal of Neurophysiology 113:3172–3185.

    https://doi.org/10.1152/jn.00113.2015

    • PubMed
    • Google Scholar
24. 1. Harriott AM
    2. Gold MS

    (2008) Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues

    Cephalalgia 28:933–944.

    https://doi.org/10.1111/j.1468-2982.2008.01635.x

    • PubMed
    • Google Scholar
25. 1. Henry MA
    2. Freking AR
    3. Johnson LR
    4. Levinson SR

    (2007) Sodium channel Nav1.6 accumulates at the site of infraorbital nerve injury

    BMC Neuroscience 8:56.

    https://doi.org/10.1186/1471-2202-8-56

    • PubMed
    • Google Scholar
26. 1. Ho C
    2. O'Leary ME

    (2011) Single-cell analysis of sodium channel expression in dorsal root ganglion neurons

    Molecular and Cellular Neuroscience 46:159–166.

    https://doi.org/10.1016/j.mcn.2010.08.017

    • PubMed
    • Google Scholar
27. 1. Hodgkin AL
    2. Huxley AF

    (1952a) Currents carried by sodium and potassium ions through the membrane of the giant axon of Loligo

    The Journal of Physiology 116:449–472.

    https://doi.org/10.1113/jphysiol.1952.sp004717

    • PubMed
    • Google Scholar
28. 1. Hodgkin AL
    2. Huxley AF

    (1952b) Propagation of electrical signals along giant nerve fibers

    Proceedings of the Royal Society B: Biological Sciences 140:177–183.

    https://doi.org/10.1098/rspb.1952.0054

    • PubMed
    • Google Scholar
29. 1. Hunter JC
    2. Tzoumaka E
    3. Haraguchi M
    4. Sangameswaran L
    5. Wong K
    6. Gogas KR
    7. Novakovic SD

    (1997)

    Differential regulation of tetrodotoxin-resistant (PN3) and tetrodotoxin-sensitive (PN1) sodium channels following peripheral nerve injury in rats

    Society Neuroscience Abstracts 23:912.

    • Google Scholar
30. 1. Jarvis MF
    2. Honore P
    3. Shieh CC
    4. Chapman M
    5. Joshi S
    6. Zhang XF
    7. Kort M
    8. Carroll W
    9. Marron B
    10. Atkinson R
    11. Thomas J
    12. Liu D
    13. Krambis M
    14. Liu Y
    15. McGaraughty S
    16. Chu K
    17. Roeloffs R
    18. Zhong C
    19. Mikusa JP
    20. Hernandez G
    21. Gauvin D
    22. Wade C
    23. Zhu C
    24. Pai M
    25. Scanio M
    26. Shi L
    27. Drizin I
    28. Gregg R
    29. Matulenko M
    30. Hakeem A
    31. Gross M
    32. Johnson M
    33. Marsh K
    34. Wagoner PK
    35. Sullivan JP
    36. Faltynek CR
    37. Krafte DS

    (2007) A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat

    PNAS 104:8520–8525.

    https://doi.org/10.1073/pnas.0611364104

    • PubMed
    • Google Scholar
31. 1. Kuba H
    2. Oichi Y
    3. Ohmori H

    (2010) Presynaptic activity regulates Na(+) channel distribution at the axon initial segment

    Nature 465:1075–1078.

    https://doi.org/10.1038/nature09087

    • PubMed
    • Google Scholar
32. 1. Laedermann CJ
    2. Abriel H
    3. Decosterd I

    (2015) Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes

    Frontiers in Pharmacology 6:263.

    https://doi.org/10.3389/fphar.2015.00263

    • PubMed
    • Google Scholar
33. 1. Laedermann CJ
    2. Pertin M
    3. Suter MR
    4. Decosterd I

    (2014) Voltage-gated sodium channel expression in mouse DRG after SNI leads to re-evaluation of projections of injured fibers

    Molecular Pain 10:19.

    https://doi.org/10.1186/1744-8069-10-19

    • PubMed
    • Google Scholar
34. 1. Lawson SN
    2. Perry MJ
    3. Prabhakar E
    4. McCarthy PW

    (1993) Primary sensory neurones: neurofilament, neuropeptides, and conduction velocity

    Brain Research Bulletin 30:239–243.

    https://doi.org/10.1016/0361-9230(93)90250-F

    • PubMed
    • Google Scholar
35. 1. Lawson SN

    (2002) Phenotype and function of somatic primary afferent nociceptive neurones with C-, Adelta- or aalpha/beta-fibres

    Experimental Physiology 87:239–244.

    https://doi.org/10.1113/eph8702350

    • PubMed
    • Google Scholar
36. 1. Lu SG
    2. Zhang X
    3. Gold MS

    (2006) Intracellular calcium regulation among subpopulations of rat dorsal root ganglion neurons

    The Journal of Physiology 577:169–190.

    https://doi.org/10.1113/jphysiol.2006.116418

    • PubMed
    • Google Scholar
37. 1. Minett MS
    2. Pereira V
    3. Sikandar S
    4. Matsuyama A
    5. Lolignier S
    6. Kanellopoulos AH
    7. Mancini F
    8. Iannetti GD
    9. Bogdanov YD
    10. Santana-Varela S
    11. Millet Q
    12. Baskozos G
    13. MacAllister R
    14. Cox JJ
    15. Zhao J
    16. Wood JN

    (2015) Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7

    Nature Communications 6:8967.

    https://doi.org/10.1038/ncomms9967

    • PubMed
    • Google Scholar
38. 1. Namer B
    2. Ørstavik K
    3. Schmidt R
    4. Kleggetveit IP
    5. Weidner C
    6. Mørk C
    7. Kvernebo MS
    8. Kvernebo K
    9. Salter H
    10. Carr TH
    11. Segerdahl M
    12. Quiding H
    13. Waxman SG
    14. Handwerker HO
    15. Torebjörk HE
    16. Jørum E
    17. Schmelz M

    (2015) Specific changes in conduction velocity recovery cycles of single nociceptors in a patient with erythromelalgia with the I848T gain-of-function mutation of Nav1.7

    Pain 156:1637–1646.

    https://doi.org/10.1097/j.pain.0000000000000229

    • PubMed
    • Google Scholar
39. 1. Nassar MA
    2. Stirling LC
    3. Forlani G
    4. Baker MD
    5. Matthews EA
    6. Dickenson AH
    7. Wood JN

    (2004) Nociceptor-specific gene deletion reveals a Major role for Nav1.7 (PN1) in acute and inflammatory pain

    PNAS 101:12706–12711.

    https://doi.org/10.1073/pnas.0404915101

    • PubMed
    • Google Scholar
40. 1. Patton DE
    2. Isom LL
    3. Catterall WA
    4. Goldin AL

    (1994)

    The adult rat brain beta 1 subunit modifies activation and inactivation gating of multiple sodium channel alpha subunits

    The Journal of Biological Chemistry 269:17649–17655.

    • PubMed
    • Google Scholar
41. 1. Qiao X
    2. Werkman TR
    3. Gorter JA
    4. Wadman WJ
    5. van Vliet EA

    (2013) Expression of sodium channel α subunits 1.1, 1.2 and 1.6 in rat Hippocampus after kainic acid-induced epilepsy

    Epilepsy Research 106:17–28.

    https://doi.org/10.1016/j.eplepsyres.2013.06.006

    • PubMed
    • Google Scholar
42. 1. Qu Y
    2. Curtis R
    3. Lawson D
    4. Gilbride K
    5. Ge P
    6. DiStefano PS
    7. Silos-Santiago I
    8. Catterall WA
    9. Scheuer T

    (2001) Differential modulation of sodium channel gating and persistent sodium currents by the beta1, beta2, and beta3 subunits

    Molecular and Cellular Neuroscience 18:570–580.

    https://doi.org/10.1006/mcne.2001.1039

    • PubMed
    • Google Scholar
43. 1. Roy ML
    2. Narahashi T

    (1992)

    Differential properties of tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in rat dorsal root ganglion neurons

    Journal of Neuroscience 12:2104–2111.

    • PubMed
    • Google Scholar
44. 1. Rush AM
    2. Elliott JR

    (1997) Phenytoin and carbamazepine: differential inhibition of sodium currents in small cells from adult rat dorsal root ganglia

    Neuroscience Letters 226:95–98.

    https://doi.org/10.1016/S0304-3940(97)00258-9

    • PubMed
    • Google Scholar
45. 1. Schmalhofer WA
    2. Calhoun J
    3. Burrows R
    4. Bailey T
    5. Kohler MG
    6. Weinglass AB
    7. Kaczorowski GJ
    8. Garcia ML
    9. Koltzenburg M
    10. Priest BT

    (2008) ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors

    Molecular Pharmacology 74:1476–1484.

    https://doi.org/10.1124/mol.108.047670

    • PubMed
    • Google Scholar
46. 1. Tseng TJ
    2. Hsieh YL
    3. Ko MH
    4. Hsieh ST

    (2014) Redistribution of voltage-gated sodium channels after nerve decompression contributes to relieve neuropathic pain in chronic constriction injury

    Brain Research 1589:15–25.

    https://doi.org/10.1016/j.brainres.2014.07.012

    • PubMed
    • Google Scholar
47. 1. Vaughn AH
    2. Gold MS

    (2010) Ionic mechanisms underlying inflammatory mediator-induced sensitization of dural afferents

    Journal of Neuroscience 30:7878–7888.

    https://doi.org/10.1523/JNEUROSCI.6053-09.2010

    • PubMed
    • Google Scholar
48. 1. Vetter I
    2. Deuis JR
    3. Mueller A
    4. Israel MR
    5. Starobova H
    6. Zhang A
    7. Rash LD
    8. Mobli M

    (2017) NaV1.7 as a pain target - From gene to pharmacology

    Pharmacology & Therapeutics 172:.

    https://doi.org/10.1016/j.pharmthera.2016.11.015

    • PubMed
    • Google Scholar
49. 1. Waxman SG
    2. Kocsis JD
    3. Black JA

    (1994)

    Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy

    Journal of Neurophysiology 72:466–470.

    • PubMed
    • Google Scholar
50. 1. Yang D
    2. Gereau RW

    (2004) Group II metabotropic glutamate receptors inhibit cAMP-dependent protein kinase-mediated enhancemednt of tetrodotoxin-resistant sodium currents in mouse dorsal root ganglion neurons

    Neuroscience Letters 357:159–162.

    https://doi.org/10.1016/j.neulet.2003.11.074

    • PubMed
    • Google Scholar
51. 1. Yu FH
    2. Yarov-Yarovoy V
    3. Gutman GA
    4. Catterall WA

    (2005) Overview of molecular relationships in the voltage-gated ion channel superfamily

    Pharmacological Reviews 57:387–395.

    https://doi.org/10.1124/pr.57.4.13

    • PubMed
    • Google Scholar
52. 1. Zhang XL
    2. Lee KY
    3. Priest BT
    4. Belfer I
    5. Gold MS

    (2015) Inflammatory mediator-induced modulation of GABAA currents in human sensory neurons

    Neuroscience 310:401–409.

    https://doi.org/10.1016/j.neuroscience.2015.09.048

    • PubMed
    • Google Scholar

Author details

1. Xiulin Zhang

   Department of Urology, The Second Hospital of Shandong University, Jinan Shi, China

   Contribution

   XZ, Data curation, Formal analysis, Methodology, Writing—original draft, Writing—review and editing

   Competing interests

   No competing interests declared.

2. Birgit T Priest

   Lilly Research Laboratories, Indianapolis, United States

   Contribution

   BTP, Conceptualization, Methodology, Writing—review and editing

   Competing interests

   BTP: Employee of Eli Lilly

3. Inna Belfer

   Office of Research on Women’s Health, National Institutes of Health, Bethesda, United States

   Contribution

   IB, Conceptualization, Project administration, Writing—review and editing

   Competing interests

   No competing interests declared.

4. Michael S Gold

   Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, United States

   Contribution

   MSG, Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Project administration, Writing—review and editing

   For correspondence

   msg22@pitt.edu

   Competing interests

   MSG: Has received grant support from Eli Lilly and Grunenthal and has served on an advisory panel for Grunenthal and the Global Pain Foundation.

   "This ORCID iD identifies the author of this article:" 0000-0002-2083-6206

• 4,283

  views

• 798

  downloads

• 76

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.